Compare Amylx Pharmaceuticals Inc (AMLX) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Mercadolibre Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Mercadolibre Inc trades at $1,853.02 (market cap $93.90B). The key difference: Mercadolibre Inc is far larger — about 47.4× Amylx Pharmaceuticals Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Amylx Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | MELI | |
|---|---|---|
Market Cap | $1.98B | $93.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $2.51K |
52-Week Low | $7.64 | $1.55K |
Enterprise Value | $1.70B | $100.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MercadoLibre (MELI) trades at $1,852.22, up 2.46% today, with a bullish technical signal from moving averages and strong analyst support (23 buy, 0 sell). Revenue grew to $28.89B in 2025, though net income margin compressed to 6.04% amid heavy investment. Recent news highlights investigations by law firms and debates over profitability versus growth, while cash flow from operations surged to $12.12B.
Outlook remains positive given dominant Latin American e-commerce position and 49% revenue growth, but risks include margin pressure from capex, legal scrutiny, and high valuation multiples. The consensus price target of $2,230 implies ~20% upside, contingent on execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
